The mood around the BIO-Europe conference in Munich in November was positive as people in the biotech world, or at least 5,500 of them, gathered to talk shop at over 30,000 partnering meetings. However once again, finance (or the lack of it) dominated many of the discussions heard around the Bavarian capital.
Europe’s Biotech Sector Still In Reasonable Shape
Money may have become too tight to mention for many biotechs and the IPO window in Europe is not just shut but boarded up. However, big pharma’s need to replenish the pipeline has become urgent and the major players are looking to tap into the continent’s early-stage companies which are driving innovation and provide them with much-needed cash.
